FDA approved Tevimbra plus chemo for first-line treatment of PD-L1-positive metastatic ESCC, showing a 34% reduced risk of death in trials. In a Phase 3 study, Tevimbra plus chemo improved median ...

Tislelizumab, combined with chemotherapy, is now FDA-approved for first-line treatment of unresectable or metastatic ESCC with PD-L1 expression. The phase 3 RATIONALE-306 study demonstrated ...

Neoadjuvant chemoimmunotherapy is associated with significantly improved survival outcomes compared with standard ...